Novo Nordisk, Wegovy
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...
China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...
One of the world’s largest drug manufacturers is suing a small east metro wellness center over the way it marketed and sold a ...
Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to ...
Injectable prescription drugs that reduce appetite — like Ozempic, Saxenda and Mounjaro — have skyrocketed in popularity in ...
Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...
Weight loss drugs have gained attention as a tool to help combat obesity, but understanding how they work, who they’re for, ...
In a society that has so many people who are overweight, it is understandable there’s such a craze for new drugs that are ...
Ozempic, Wegovy, Zepbound, and Mounjaro are but a few of the injectable drugs that are currently revolutionizing the size of ...
In the heavyweight title match between weight loss meds, we have ourselves a victor.In the battle between Novo Nordisk’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback